Browse Drug Recalls
23 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 23 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 23 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Nov 22, 2023 | SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL b... | Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals | Class I | Novartis Pharmaceuticals Corporation |
| Sep 8, 2023 | SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL b... | Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals. | Class I | Novartis Pharmaceuticals Corp. |
| Sep 16, 2022 | Neoral soft gelatin capsules (cyclosporine capsules, USP) Modified, 25 mg, Rx... | CGMP deviations: Out of specification results obtained during routine stability testing for ethan... | Class II | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Contai... | Failed Impurities/Degradation Specifications. | Class III | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | Xiidra (lifitegrast ophthalmic solution) 5%, packaged in a) 60 Single-Use Con... | Failed Impurities/Degradation Specifications. | Class III | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in ... | Failed Impurities/Degradation Specifications. | Class III | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in ... | Failed Impurities/Degradation Specifications. | Class III | Novartis Pharmaceuticals Corporation |
| May 11, 2019 | Promacta (eltrombopag) 12.5 mg for Oral Suspension, Rx Only Manufactured by:... | Cross Contamination with Other Products: product is being recalled due to possible cross-contamin... | Class I | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Tekturna (aliskiren) Tablets 300 mg, 7 tablets per bottle, Physician Sample-N... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge (amlodipine and valsartan Tablets) 5/320 mg, Rx only 7 tablets per bo... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Tekturna HCT (aliskiren and hydrochlorothiazide) Tablets 300/25 mg, 7 tablets... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Diovan (valsartan) 320 mg per tablet, 7 Tablets per bottle, Rx only Physicia... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Lescol XL (fluvastatin sodium) Extended-Release Tablets, 80 mg per tablet, 7 ... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Tekturna HCT (aliskiren and hydrochlorothiazide) Tablets 150/12.5 mg, 7 table... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Diovan (valsartan) 160 mg per tablet, 7 Tablets per bottle, Rx only Physicia... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) 10/320/25 mg, Rx onl... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge (amlodipine and valsartan, Tablets) 10/320 mg, Rx only, 7 tablets per... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) 5/160/12.5 mg, Rx on... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge (amlodipine and valsartan Tablets) 10/160 mg, Rx only, 7 tablets per ... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge (amlodipine and valsartan Tablets) 5/160 mg, Rx only 7 tablets per bo... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Stalevo (carbidopa, levodopa, and entacapone) 12.5/50/200 mg, 7 tablets per b... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Tekturna (aliskiren) Tablets 150 mg, 7 tablets per bottle, Physician Sample-N... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
| Aug 8, 2013 | Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) 5/160/25 mg, Rx only... | Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottle... | Class II | Novartis Pharmaceuticals Corp. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.